Shanghai Medicilon Inc. (SHA:688202)
100.47
-9.53 (-8.66%)
At close: Aug 21, 2026
Shanghai Medicilon Revenue
Shanghai Medicilon had revenue of 364.64M CNY in the quarter ending March 31, 2026, with 36.52% growth. This brings the company's revenue in the last twelve months to 1.26B, up 20.59% year-over-year. In the year 2025, Shanghai Medicilon had annual revenue of 1.16B with 12.08% growth.
Revenue (ttm)
1.26B
Revenue Growth
+20.59%
P/S Ratio
10.48
Revenue / Employee
503.44K
Employees
2,504
Market Cap
13.22B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.16B | 125.32M | 12.08% |
| Dec 31, 2024 | 1.04B | -327.89M | -24.01% |
| Dec 31, 2023 | 1.37B | -293.30M | -17.68% |
| Dec 31, 2022 | 1.66B | 491.67M | 42.12% |
| Dec 31, 2021 | 1.17B | 501.31M | 75.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Anke Biotechnology (Group) | 2.56B |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Jinyu Bio-technology | 1.53B |
| Sinocelltech Group | 1.36B |
| BrightGene Bio-Medical Technology | 1.30B |
| Acrobiosystems | 887.21M |
| GemPharmatech | 878.13M |
| Mabwell (Shanghai) Bioscience | 745.32M |